Data from Pharmawand - Curated by Toby Galbraith - Date added 11 September 2017

Eli Lilly and Company presented key primary and secondary endpoint data at the 18th Congress of the International Headache Society (IHC for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, which demonstrated statistically significant improvements compared to placebo in the Phase III SPARTAN study.

At two hours following the first dose, a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo. These results were statistically significant across all three studied doses (50 mg, 100 mg and 200 mg). A statistically significantly greater percentage of patients were also free of their most bothersome symptom (MBS) compared with placebo at two hours. In this study, patients chose their MBS from nausea, sensitivity to sound or sensitivity to light. The majority of patients treated with lasmiditan also experienced relief from migraine pain—classified as mild or no pain—at two hours following the first dose (59 percent for 50 mg, 64.8 percent for 100 mg and 65 percent for 200 mg, p < 0.001 for all dosing groups).

These results were statistically significant compared to placebo (47.7 percent). In this study, fewer patients treated with lasmiditan took a second, rescue dose of treatment compared to placebo (41 percent for 50 mg; 32.7 percent for 100 mg; 26.4 percent for 200 mg and 49.8 percent for placebo).


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Airway Disease

The Airway Disease Learning Zone is an area where you can access the information about VisionAir and see video presentations from the forum. The Inhalation Technology page features a video presentation from the live broadcast presented by key faculty.

Visit Airway Disease

Allergic Rhinitis

Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.

Visit Allergic Rhinitis

Related Content